# Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct04817215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04817215](<https://clinicaltrials.gov/study/NCT04817215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04817215

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 608 participants.

## Technical summary

Registry record NCT04817215. Randomized; double masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2022-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 608 participants (planned count; ClinicalTrials.gov record NCT04817215, source copy `cardio:ctgov-nct04817215-2021-03-26`, retrieved 2026-10-26)
- Planned start: 2021-10 (anticipated) (ClinicalTrials.gov record NCT04817215, source copy `cardio:ctgov-nct04817215-2021-03-26`, retrieved 2026-10-26)
- Primary completion: 2022-04 (anticipated) (ClinicalTrials.gov record NCT04817215, source copy `cardio:ctgov-nct04817215-2021-03-26`, retrieved 2026-10-26)
- Completion: 2022-07 (anticipated) (ClinicalTrials.gov record NCT04817215, source copy `cardio:ctgov-nct04817215-2021-03-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04817215-2021-03-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): ORMD-0801
- Lead sponsor: King Hamad University Hospital, Bahrain
- Lead sponsor class: OTHER
- Collaborator: Royal College of Surgeons in Ireland - Medical University of Bahrain
- Collaborator class: OTHER
- Collaborator: Oramed, Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Oramed, Ltd. (`cardio:org-oramed-ltd`)

## Provenance

Content hash: 66f9869274edc22a2af03dc346835be6401d7859cf27f2685364c88a10d7f1ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
